Dynamic Technology Lab’s KalVista Pharmaceuticals KALV Stock Holding History

Dynamic Technology Lab’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-13,113	Closed	-$89K	–	1317
2022 Q4	$89K	Buy	+13,113	New	+$70.2K	0.01%	1002
2022 Q3	–	Sell	-13,969	Closed	-$137K	–	1332
2022 Q2	$137K	Buy	+13,969	New	+$154K	0.02%	959

Other funds holding KALV

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Dynamic Technology Lab's KALV Position: Q1 2023 in Review

Dynamic Technology Lab sold out of KalVista Pharmaceuticals (KALV) in Q1 2023, closing a stake of 13,113 shares — an estimated $89K sold.

Dynamic Technology Lab first reported a position in KALV in Q2 2022 and held it in 2 quarters. The position peaked at $137K in Q2 2022. 88 funds tracked by Wall St. Rank hold KALV as of Q1 2023.

Dynamic Technology Lab reported no remaining KalVista Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Dynamic Technology Lab sold 13,113 KalVista Pharmaceuticals shares in Q1 2023, an estimated $89K.
Dynamic Technology Lab first reported a position in KalVista Pharmaceuticals in Q2 2022 and held it in 2 quarters.
Dynamic Technology Lab's KalVista Pharmaceuticals position peaked at $137K in Q2 2022.
88 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2023.

Based on Dynamic Technology Lab's 13F filing for Q1 2023, filed 12 May 2023.